| Company Name: |
Guangzhou Isun Pharmaceutical Co., Ltd
|
| Tel: |
020-39119399 18927568969 |
| Email: |
isunpharm@qq.com |
| Products Intro: |
Product Name:clopidogrel hydrochloride
CAS:130209-90-4
Purity:>=98% Package:500Mg;1g;5g;25g;100g;500g;1kg;5kg
|
|
| | (R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride Basic information |
| Product Name: | (R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride | | Synonyms: | METHYL 2-(2-CHLOROPHENYL)-2-(4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDIN-5-YL)ACETATE HYDROCHLORIDE;(R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetateHCl;(R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride;(+/-)-Clopidogrelhydrochloride;(+/-)-Clopidogrel hydrochloride
DISCONTINUED;Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate hydrochloride | | CAS: | 130209-90-4 | | MF: | C16H17Cl2NO2S | | MW: | 358.28 | | EINECS: | | | Product Categories: | | | Mol File: | 130209-90-4.mol | ![(R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride Structure](CAS/20180906/GIF/130209-90-4.gif) |
| | (R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS(pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 5 mg/ml | | form | A crystalline solid |
| | (R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride Usage And Synthesis |
| Description | Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM).1,2 Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity.3 Marketed under the name Plavix?, clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.4 | | storage | +4°C (desiccate) | | References | 1. Savi, P., Labouret, C., Delesque, N., et al. P2Y12, a new platelet ADP receptor, target of clopidogrel Biochem. Bioph. Res. Commun. 283(2),379-383(2001).
2. von Kügelgen, I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes Pharmacol. Ther. 110(3),415-432(2006).
3. Quinn, M.J., and Fitzgerald, D.J. Ticlopidine and clopidogrel Circulation 100(15),1667-1672(1999).
4. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives J. Am. Coll. Cardiol. 49(14),1505-1516(2007). |
| | (R,S)-Methyl-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothino[3.2-c]pyridin-5-yl)acetatehydrochloride Preparation Products And Raw materials |
|